Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic cyclophosphamide + capecitabine + vinorelbine in metastatic breast cancer
2010-024266-21Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Dec 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, capecitabine and vinorelbine in breast cancer, sponsored by European Institute of Oncology. Primary endpoint: Time to progression. Started Dec 2011; status: completed.
02
Drugs
cyclophosphamidecapecitabinevinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-024266-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024266-21.